LEGN Legend Biotech (LEGN) Q2 FY26 earnings call
Legend Biotech delivered a strong second quarter, achieving its first company-wide profitability driven by robust CARVYKTI sales and increasing adoption in earlier lines of therapy. The company also reported compelling early clinical data for its in vivo CAR-T platform, particularly LB2501, and plans a US IND submission by year-end. Despite a leadership transition, the strategic focus remains on maximizing CARVYKTI, advancing the pipeline, and strengthening execution, supported by a strong financial position.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
LEGN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Global treatment sites | 294Our global growth was driven by continued share gains, site expansion and growing geographic footprint, now reaching 294 global treatment sites across 14 markets worldwide.Source: earnings call transcript | 300+Outside the US demand was supported by continued uptake in established European markets and contributions from recent launches with CARVYKTI now available across 18 global markets and more than 300 global treatment sites.Source: earnings call transcript | 348We recently launched CARVYKTI in Ireland, further expanding availability to 348 global treatment sites, reflecting continued geographic expansion with our partner, J&J Across geographies, we continue to see encouraging trends in both market penetration and earlier line utilization.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.